Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

GSK Pushing For ADOPTion Of Avandia For First-Line Type 2 Diabetes Therapy

  • News

Executive Summary

GlaxoSmithKline plans to use the results of its ADOPT study to establish its thiazolidinedioneAvandia as the standard first-line treatment for type 2 diabetes

You may also be interested in...



GSK Hopes RECORD Sets Avandia Straight; Firm’s Diabetes Pipeline Bleak

If GlaxoSmithKline's Avandia is brought down by a potential cardiovascular safety signal, the firm will not have diabetes products graduating from its pipeline in the near term to fill the void

GSK Hopes RECORD Sets Avandia Straight; Firm’s Diabetes Pipeline Bleak

If GlaxoSmithKline's Avandia is brought down by a potential cardiovascular safety signal, the firm will not have diabetes products graduating from its pipeline in the near term to fill the void

GSK Plays Up Avandia As Diabetes “Engine” After DPP-4 Program Stalls

GlaxoSmithKline does not believe development of its own dipeptidyl peptidase-4 inhibitor is integral to growing the firm's diabetes franchise

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

Changes To EU Pharma Reform: More Questions Than Answers?

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

See All
UsernamePublicRestriction

Register

PS047826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By